• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Propeller Health, Novartis ink collaboration for connected inhaler

February 8, 2017 By Sarah Faulkner

Propeller Health, Novartis ink collaboration for connected inhalerPropeller Health said today that it landed a collaborative agreement with Novartis (NYSE:NVS) to develop a custom add-on sensor for the Breezhaler inhaler. The partnership is focused on patients with chronic obstructive pulmonary disease in Europe.

The Breezhaler is a capsule-based, dry powder inhaler and is a part of Novartis’ portfolio of COPD therapies. The custom sensors developed as a result of this collaboration will passively record and transmit compliance data, according to Propeller, which will better inform patients and physicians of adherence.

“We’re excited to work with the team at Novartis to connect the Breezhaler device to the Propeller platform. The addition of this major respiratory franchise represents an important next step in our mission to bring valuable digital companions to everyone’s respiratory treatments,” Propeller CEO David Van Sickle said in prepared remarks. “With data from these medication sensors and interfaces, Propeller strengthens the relationships between patients and their physicians and helps them build effective treatment programs together.”

In December, Propeller inked a deal with Medical International Research to integrate MIR’s mobile and clinical spirometers into the Propeller system.

A month earlier, the company said that it won 510(k) clearance from the FDA to market its Propeller platform with GlaxoSmithKline‘s (NYSE:GSK) Ellipta inhaler. A sensor for the dry powder inhaler was built as a part of a 1 year-long development and R&D collaboration between Propeller and GSK.

This marked the 8th clearance for Propeller’s connected inhaler platform.

The Madison, Wisconsin-based company won CE Mark approval and Health Canada registration for the use of its connected platform with the Ellipta inhaler earlier last year.

Filed Under: Drug-Device Combinations, Featured, Research & Development, Respiratory, Wall Street Beat Tagged With: Novartis, Propeller Health

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS